Learnings from phosphatidylinositol 3-kinase inhibitors in lymphoma—Moving to a model where less can be more

Arina Martynchyk, Eliza A. Hawkes

Research output: Contribution to journalComment / DebateOtherpeer-review


The role of Pi3K inhibitors in lymphoma is diminishing due to the adverse results from trials in indolent lymphoma, but is a one-size-fits-all approach to drug development penalising some lymphoma subtypes and the newer generation of Pi3K inhibitors? The report by Soumerai et al. of zandelisib with zanubrutinib in follicular and mantle cell lymphoma is an important addition to the data. Commentary on: Soumerai et al. Safety and efficacy of zandelisib plus zanubrutinib in previously treated follicular and mantle cell lymphomas. Br J Haematol 2024 (Online ahead of print). https://doi.org/10.1111/bjh.19419.

Original languageEnglish
Pages (from-to)1582-1584
Number of pages3
JournalBritish Journal of Haematology
Issue number5
Publication statusPublished - May 2024


  • lymphoma
  • Pi3K inhibitors
  • zandelisib

Cite this